Octocog alfa - Bayer

Drug Profile

Octocog alfa - Bayer

Alternative Names: Factor VIII - Bayer; Helixate; Kogenate; Recombinant factor VIII - Bayer

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Ipsen
  • Developer Bayer
  • Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Market Withdrawal Haemophilia

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 19 Nov 2002 Bayer's research collaboration with PolyMASC (Valentis) has expired and Bayer has decided not to enter into any further agreement
  • 19 Nov 2002 Bayer and PolyMASC have completed the feasibility study examining the use of PolyMASC's ProtoMASC technology for possible development of a chemically-modified factor VIII
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top